How a discontinued Alzheimer’s drug study got a second life

“MY FIRST REACTION WAS TO BE ANGRY,” SAYS JOANN Wooding. “I’ve gotten over that, and is more the word right now.” Wooding’s husband Peter, who was diagnosed with Alzheimer’s in 2016, was among the more than 3,200 people with the disease who volunteered to test a promising drug called aducanumab. In earlier study results released the same year, the drug, developed by Biogen, a U.S. biotech company, and Eisai, a Japanese pharmaceutical manufacturer, seemed to accomplish a number of firsts for people with Alzheimer’s. It appeared to shrink deposits of the protein amyloid accumulating in the brains of patients and, perhaps more important, also slow the cognitive decline

Vous lisez un aperçu, inscrivez-vous pour en lire plus.

Plus de TIME

TIME9 min de lecture
The News Gets To Move On
The therapy and medication helped. So did a pottery class. Anything to take her mind off that day. Then Pacella retraumatized herself. In February, she testified before a state legislative committee in support of a bill that would regulate rifles and
TIME3 min de lecture
Olivia Colman dons The Crown
IN THE 1960S, AS THE BRITISH ECONOMY stagnated and youth movements raged against the establishment, the royal family started to worry. How long could a largely ornamental monarchy keep justifying its tax-supported existence to its broke, disaffected
TIME7 min de lecture
Dimming the Lights
EVERYONE HAS AN OPINION ABOUT WHERE Felicia Anna works. For the past nine years, the 33-year-old Romanian sex worker has attracted clients by standing in the glowing windows of the world’s most famous red-light district. The area’s reputation, she sa